Compare Silicon Motion Technology Corporation American Depositary Shares (SIMO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Silicon Motion Technology Corporation American Depositary Shares vs TG Therapeutics Inc — how do they compare? Silicon Motion Technology Corporation American Depositary Shares trades at $221 (market cap $8.36B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: Silicon Motion Technology Corporation American Depositary Shares and TG Therapeutics Inc are close in size by market cap, and Silicon Motion Technology Corporation American Depositary Shares pays a 0.81% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Silicon Motion Technology Corporation American Depositary Shares for 0 Days and TG Therapeutics Inc for 16 Days on average.
| SIMO | TGTX | |
|---|---|---|
Market Cap | $8.36B | $8.32B |
Volume | 663,682 | 1,001,204 |
Sector | Technology | Health |
52-Week High | $336.90 | $59.06 |
52-Week Low | $80.16 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $8.35B | $8.52B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Silicon Motion Technology Corporation American Depositary Shares
Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
